ABSTRACT -Background and Objectives: Studies have shown showed that delirium affects the long-term functional status, however, the acute effect of delirium on functioning has been less documented. The purpose of this analysis was to examine the acute impact of delirium on the level of functioning.
Background
Delirium is associated with poor functional outcome, increased morbidity and mortality, as well as prolonged hospitalization 1 , and is a common event in the course of hospitalization depending on the age of the patient and the severity of the illness 2, 3 . In the general hospital setting, 14-24% of older patients present with delirium on admission, and 6-56% will develop delirium during the course of hospitalization 4 . In this setting, the occurrence of delirium is high and varies in medically ill patients between 15-30%, in the hospitalized elderly between 10-40% 4, 5 , in cancer patients between 57-85%, and in terminal illness, the incidence of delirium can reach up to 85% [6] [7] [8] .
Several studies have indicated that the incidence of delirium prolongs hospitalization and that in particular in older patients, delirium has an impact on the cognitive and functional status with or without dementia [9] [10] [11] . In addition, delirium has been shown to lead to an acute decline in functional status 12 , to be one of the most common reasons for admission to the hospital in patients with advanced cancer and to herald an even greater decline in performance 13 . In fact, the effect on the functional status is prominent. The impairment in the level of functioning may last up to 12 months [9] [10] [11] , thus representing a challenge in the process of recovery for the elderly and demented. Further, an association between the length of persistence of delirium symptoms and functional recovery has been documented. The persistence of delirium symptoms for less than two weeks was associated with excellent functional recovery, whereas persistence for a longer time was associated with less favorable outcomes 14 . Even more, delirium predicted greater mortality and accelerated cognitive decline in dementia [15] [16] [17] .
The current literature suggests that delirium has an impact on the functional status. Most studies focused on the long-term effect on the functional status, whereas results documenting the acute impact of delirium remain scarce. In order to further explore the impact of delirium on functioning, an analysis in respect to the level of functioning, contributing etiological factors and delirium resolution was performed.
Methods

Patients
All patients were recruited from patients referred for delirium management to the Memorial Sloan Kettering Cancer Center (MSKCC) Psychiatry Service from July to November 2000 and from July 2004 to June 2006. MSKCC is a 452 bed private hospital specializing in the treatment of cancer, averaging more than 20,000 admissions every year. The Consultation-Liaison Psychiatry Service performs on average more than 2,000 consultations yearly.
The main inclusion criterion was meeting the DSM-IV-TR 18 criteria for delirium. Exclusion criteria included patient or family objections to pharmacologic intervention, inability to participate with delirium rating, and severe agitation interfering with the interview.
All patients and their families provided verbal consent to be evaluated and receive antipsychotics for symptomatic relief of delirium. In patients with limited capacity to provide consent, the patient's primary caregiver provided verbal consent alongside the patient's assent to intervention. When patients or families were not willing to be evaluated or did not agree to management with antipsychotics, their data was not recorded. All data was obtained from the routine daily clinical care of patients diagnosed with delirium documenting the course of delirium, entered into the IRB-approved-database for subsequent analysis and was a waiver obtained for the analysis.
Measurements
Delirium severity was measured with the MDAS 20 , a 10-item, four-point clinician-rated scale (possible range 0-30) 20 . Scale items assess the disturbance in arousal and level of consciousness, as well as several areas of cognitive functioning, psychomotor activity, and sleep-wake cycle. An MDAS score of >10 identifies the presence of delirium 21, 22 . Delirium severity is categorized by using the MDAS scores as follows: mild delirium (MDAS<16), moderate delirium (MDAS 16-22) and severe delirium (MDAS>22). The MDAS uses psychomotor behavior for the subtypes of delirium and was based on the predominant presentation, hypoactive or hyperactive psychomotor behavior.
The level of functioning was assessed with the Karnofsky scale of Performance Status (KPS), indicating physical performance ability 19 . The KPS has been validated for the functional assessment of cancer patients and ranges from 10-100. In particular, scores of less than 50 indicate an inability to care for oneself and therefore require hospital care. A score of 40 indicates disability with the need for assistance and a score of 30 indicates severe disability and indicates the need for hospital admission. A score of 20 indicates the necessity of hospital admission in a very sick patient requiring active treatment and a score of 10 indicates being moribund.
MDAS and KPS rating were performed by the fellows of the consultation-liaison psychiatry service who were trained by William Breitbart 20 who established the MDAS. Inter-rater reliability was performed between fellows, however, not formally evaluated as the purpose of the database was the documentation of clinical routine and the course of delirium.
Procedures
Sociodemographic and medical variables, such as age, sex, cancer diagnosis, stage of can cer (localized, metastatic, or terminal), psychiatric diagnosis including pre-existing dementia, presence of brain metastases, and delirium etiologies were collected at the baseline assessment. Antipsychotic medication was initiated upon diagnosis of delirium and adjusted as determined by clinical response. In accordance with the guidelines for the treatment of delirium 23 , the standard approach was to manage delirium with antipsychotics and continue the necessary medical treatment, including risk factors for delirium such as the administration of opiates or corticosteroids, and to treat reversible underlying causes such as hypoxia and infection.
MDAS, KPS and side effect rating were performed at baseline (T1), repeated at 2-3 days (T2) and 4-7 days (T3), Rating was performed once on the indicated days, usually in the early afternoon. After seven days, the observation period ended. Patients were continued on antipsychotic medication as necessary.
Statistical Analysis
Data analyses were performed with the Statistical Package for the Social Sciences (SPSS) 20 for Windows. The primary interests were resolved and persistent delirium. The secondary interests were functional recovery versus functional impairment, in addition to sociodemographic and medical variables, as well as delirium severity.
In a first step, the dataset was defined as a dichotomous variable with two levels: Resolved delirium and persistent delirium. The dichotomous set was analyzed in respect to the level of functioning (KPS). In a second step, medical variables that were associated with an improvement in the level of functioning of less than 10 on the KPS representing patients with functional impairment were identified and then defined as a dichotomous variable accordingly. The comparison group was defined as patients with KPS improvement of more than 10 representing functional recovery. In the functionally-impaired, KPS scores were 22.7 (10-30, SD 5.4) at baseline and, 22.1 (10-30 SD 5.8) at T3. In the functionally-recovered, KPS scores were 25.1 (20-40, SD 5.9) and 41.3 (30-70, SD 10.6), respectively. At T3, the level of functioning was superior in the functionally-recovered (t-test: t = -11.4(109), p<0.001).
The t-test for independent variables was computed for continuous variables, such as the age of patients, medication dosing, MDAS and KPS scores between subsets and the oneway ANOVA for multiple, independent measures such as the description of the level of functioning in mild, moderate and severe delirium. The ANOVA repeated measures test was used for repeated measures of dependent variables, such as subsequent MDAS and KPS scores. Pearson's Chi-square test was used for categorical variables such as the prevalence of terminal illness in haloperidolmanaged patients. In order to analyze the effect of medical variables on functional impairment and recovery, multivariate logistic regression analyses were performed.
The significance level alpha (α) was set at p<0.05.
Results
Baseline characteristics
Overall, 111 cases of delirium managed with haloperidol, risperidone, olanzapine and aripiprazole for delirium were retrieved. The patients had an advanced age, were predominantly male, and hypoactive delirium and hyperactive delirium were equally distributed. Cancer diagnoses were diverse and delirium was generally multifactorial (table 1) .
Description of the level of functioning
The functional status was impaired at baseline and improved throughout the management period. KPS scores increased from 24.1 at baseline, to 28. Between patients with resolved and persistent delirium, KPS scores were not different at baseline, however, at T2 and T3, KPS scores and thus the level of functioning were higher 
Patients with functional impairment
Patients with functional recovery or impairment were not different in age, by pre-existing dementia, or brain metastases (table 1   and 3 ). There was a trend towards brain cancer (16.7% and 6.3%) contributing to functional impairment and terminal cancer contributed to functional impairment (28.3% and 9.5%). Among etiologies, only hypoxia (50% and 27%) and multiple etiologies caused more severe functional impairment (table 2) .
There were also few differences in management characteristics (table 3) . Hypoactive and hyperactive delirium was similarly distributed with 50% in the functionally-impaired compared to 41.3% and 58.7% in the functionally-recovered. There were no differences in respect to the dosing of risperidone, olanzapine or aripiprazole between the functionally-impaired and -recovered. Only, when haloperidol was administered higher doses were given to the functionally-recovered (2.9 mg and 6.2 mg). However, there was also a trend towards the functionallyimpaired managed with haloperidol being older (68.3, 42-86, SD 13.3 vs. 58.4, 23-78, SD 13.9, t-test: t = 1.82(2), p = 0.078) and suffering more often from terminal illness (31.3% and 5.3%, χ 2 (1) 4.13, p = 0.073).
Furthermore, there were no differences in MDAS scores at baseline (18.2 and 18.3) , at T2 and T3 however, delirium was more severe in the functionally-impaired. MDAS scores at T2 were 13.1 and 8.9 and at T3 were 10.6 and 6.0 indicating the functionallyimpaired did not achieve delirium resolution. Although MDAS scores decreased in all patients, the delirium resolution was inferior in the functionally-recovered: At T2, delirium resolution was 63.5% and 25% and at T3, 87.3% and 62.5%, respectively. On the contrary, functional recovery was associated with shorter delirium. Whereas the level of functioning expectedly improved in the functionally-recovered, the functionally-impaired did not achieve improvement in KPS scores or the level of functioning.
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Discussion
These findings suggest that delirium had an acute impact on the level of functioning in the course of hospitalization and that active management of delirium with antipsychotics reversed this effect. On the contrary, shorter delirium was associated with functional recovery. In this respect, these results confirmed previous findings which have shown that delirium has an acute impact on the level of functioning 13 , however, add new insights into the necessity of active management with antipsychotics in order to reverse this effect. Furthermore, brain cancer, terminal illness, hypoxia, and multiple etiologies were confounders for persistent delirium and functional impairment.
It is known that delirium has a long-term effect on cognitive and functional status in older patients with or without dementia [9] [10] [11] . Also, an interaction between the length of persistence of delirium symptoms and functional recovery has been documented: The shorter the persistence of delirium symptoms, the better the functional recovery has been. In particular, persistence of delirium for less than two weeks has been associated with excellent functional recovery 14 .
Similarly, within one week of observation, the functional recovery was also superior with a shorter duration of delirium as documented by the functionally-recovered in contrast to the functionally-impaired. Although at baseline, no differences in delirium severity between the functionally-impaired andrecovered existed, in the course of management, more severe and persistent delirium became apparent in the functionally-impaired at T2 and T3. Thus, the necessity of actively managing delirium in order to accelerate the functional recovery process and prevent increased morbidity, mortality and rates of institutionalization 1 ought to be a primary goal and while previously shown in the long-term setting, extended to the acute care setting.
Surprisingly, the severity of delirium, mild, moderate, or severe, did not affect the functional status independently, interesting aspects remain. Persistent delirium had an impact on the functional status in the acute care setting and, in contrast, the level of functioning improved with delirium resolution. This indicated that successful management of delirium with antipsychotics caused the reversal of functional impairment. This effect extended to patients with persistent delirium in whom the level of functioning also improved, however, the improvement was less pronounced.
At baseline, there were no differences in functional status between the functionallyimpaired and -recovered. Over the course of management, the functional status of patients with resolved delirium improved and was superior to patients with persistent delirium. Of interest, this effect appeared to affect all patients with delirium in contrast to previous studies that found persistent delirium in older patients over several months. Still, patients with persistent delirium and lower KPS scores were older than patients with resolved delirium (71.3 and 63.8 years), which implied that advanced age could be associated with a protracted and refractory course of delirium and a more severe and prolonged impact on the level of functioning.
As medical factors may contribute to functional impairment, these variables were identified by examining cases with functional impairment. There were no differences with respect to age, pre-existing dementia, or brain metastases, except for an increased prevalence of brain cancer, terminal illness, hypoxia, and multiple etiologies in the functionally-impaired. These factors were confounded persistent delirium as has been previously shown 8, 24, 25 .
With respect to the adequacy of management, the dosing of antipsychotic medication did not appear to have an effect on functional improvement. When risperidone, olanzapine, or aripiprazole were administered, no differences existed between the functionally-impaired and -recovered. Only in patients managed with haloperidol higher doses were administered to the functionally-recovered. However, these patients tended to be older and terminal illness was present at a higher rate, which in part could have explained differences in haloperidol dosing. Overall, the medication doses administered were comparable to those in existing studies 26 .
There are a number of limitations to be noted. Although the design of the data collection was prospective, it was not possible to follow patients prior to the onset of delirium and measure the impact of delirium in a prospective manner. Instead, the reversal of impairment in the level of functioning was described and deduced on the impact of delirium on the level of functioning. Due to the design of the data collection, measuring the first MDAS upon presentation with delirium, it was not possible to obtain a baseline cognitive assessment of functional assessment. Further, the observation period was limited to one week and a longer observation period would have been preferable. In addition, there was a selection of patients with delirium through the referral process, as well as an exclusion of patients unable or unwilling to comply with rating. Although all rater were trained by the creator of the MDAS and interrater reliability was performed, no formal evaluation of the inter-rater reliability was recorded. The delirium database contained data of the management of delirium with aripiprazole, haloperidol, risperidone, and haloperidol. Delirium was classified as hypoactive and hyperactive by predominant presentation, the mixed subtype was not assigned. All patients were naturally assigned to a medication, the assignment was not random. All patients had cancer diagnoses and the generalizability of results to the non-cancer population remains to be evaluated. The use of antipsychotics in the management of delirium has not been approved by the regulatory agencies, and the use of antipsychotics in the elderly patients with dementia carries a black box warning of increased risk of death 27, 28 . Yet, this analysis may be another step towards demonstrating the acute impact of delirium on the level of functioning, the reversibility of this effect by management with antipsychotics, and warrants future studies with a prospective design.
In summary, this analysis suggests that delirium had an acute impact on the level of functioning which was reversible with the appropriate management of delirium. On the contrary shorter delirium was associated with functional recovery. Brain cancer, terminal illness and hypoxia were confounders to persistent delirium and functional impairment.
